RE:Acumen Pharmaceuticals IncIt's interesting that calcium screening identifies antibody candidates without otherwise characterizing the associated oligomer(s). So in theory PMN310 could be tested this way, or a model of ACU193 could be tested virtually against Promis' epitopes. Assuming both companies believe they have the better antibody they could swap some info and both come out ahead.